NewLink Genetics Corp (NLNK) Given Average Rating of “Buy” by Brokerages

Shares of NewLink Genetics Corp (NASDAQ:NLNK) have earned an average recommendation of “Buy” from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $25.67.

A number of brokerages have issued reports on NLNK. Zacks Investment Research raised shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $9.00 price objective on the stock in a research note on Wednesday, January 3rd. BidaskClub raised shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. Bank of America initiated coverage on shares of NewLink Genetics in a research report on Friday, October 13th. They set a “buy” rating and a $22.00 price target on the stock. Jefferies Group reduced their price target on shares of NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. Finally, Stifel Nicolaus lifted their price target on shares of NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd.

Several hedge funds and other institutional investors have recently made changes to their positions in NLNK. Wells Fargo & Company MN boosted its position in shares of NewLink Genetics by 1.8% during the second quarter. Wells Fargo & Company MN now owns 165,791 shares of the biotechnology company’s stock worth $1,219,000 after purchasing an additional 2,865 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of NewLink Genetics by 88.6% during the second quarter. Alliancebernstein L.P. now owns 61,300 shares of the biotechnology company’s stock worth $451,000 after acquiring an additional 28,800 shares during the period. Northern Trust Corp raised its holdings in shares of NewLink Genetics by 4.0% during the second quarter. Northern Trust Corp now owns 298,738 shares of the biotechnology company’s stock worth $2,195,000 after acquiring an additional 11,532 shares during the period. Advisor Group Inc. raised its holdings in shares of NewLink Genetics by 3.4% during the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 600 shares during the period. Finally, Parametric Portfolio Associates LLC raised its holdings in shares of NewLink Genetics by 21.5% during the second quarter. Parametric Portfolio Associates LLC now owns 27,972 shares of the biotechnology company’s stock worth $206,000 after acquiring an additional 4,955 shares during the period. 52.68% of the stock is currently owned by institutional investors.

Shares of NewLink Genetics (NLNK) traded down $0.76 during mid-day trading on Friday, reaching $6.81. 1,705,781 shares of the company’s stock were exchanged, compared to its average volume of 640,079. NewLink Genetics has a 1 year low of $5.90 and a 1 year high of $25.17. The company has a market capitalization of $280.67, a PE ratio of -2.79 and a beta of 1.15.

WARNING: “NewLink Genetics Corp (NLNK) Given Average Rating of “Buy” by Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/10/newlink-genetics-corp-nlnk-given-average-rating-of-buy-by-brokerages.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply